SEC 13F Intelligence

Managers / Q3 2022 · view latest →

SECTORAL ASSET MANAGEMENT INC

CIK 0001274413 · 1010 SHERBROOKE ST., WEST, SUITE 1610, MONTREAL, A8, H3A 2R7 · 514 849 8777

Reported Value
$508M
Q3 2022
Positions
109
Filings on Record
30
2019–present window
Filed
Nov 10, 2022
original filing

Summary

Sectoral Asset Management Inc reported $508M in U.S.-listed holdings across 109 positions for Q3 2022.

Its largest position, UNH, represents 3.3% of the portfolio.

Compared with Q2 2022, the fund opened 10 new positions and exited 13.

Portfolio Metrics

Turnover
+15.0%
vs prior filed quarter
Top-10 Concentration
+26.1%
share of reported value
Largest Position
+3.3%
Unitedhealth
New / Exited
10 / 13
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $736MQ4 ’18Q1 ’19: $831MQ2 ’19: $836MQ3 ’19: $580MQ4 ’19: $670MQ4 ’19Q1 ’20: $521MQ2 ’20: $1.1BQ3 ’20: $1.2BQ4 ’20: $1.4BQ4 ’20Q1 ’21: $1.3BQ2 ’21: $1.2BQ3 ’21: $1.2BQ4 ’21: $664MQ4 ’21Q1 ’22: $563MQ2 ’22: $496MQ3 ’22: $508MQ4 ’22: $517MQ4 ’22Q1 ’23: $520MQ2 ’23: $600MQ3 ’23: $514MQ4 ’23: $232MQ4 ’23Q1 ’24: $254MQ2 ’24: $246MQ3 ’24: $169MQ4 ’24: $150MQ4 ’24Q1 ’25: $128MQ2 ’25: $151MQ3 ’25: $162MQ4 ’25: $125MQ4 ’25Q1 ’26: $121Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 88.4%Other: 10.8%ADR: 0.9%
  • Common Stock · 88.4% · $448M
  • Other · 10.8% · $55M
  • ADR · 0.9% · $4M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CINCOR PHARMA INCNEW+195.5K195.5K+$6M$6M
AMLXAMYLYX PHARMACEUTICNEW+205.4K205.4K+$6M$6M
CTIC1USDCTI BIOPHARMA CORPNEW+968.3K968.3K+$6M$6M
SPRYSILVERBACK THERAPEUTNEW+1.05M1.05M+$6M$6M
SGFYGBPSIGNIFY HEALTH INCNEW+150.0K150.0K+$4M$4M
BEAMBEAM THERAPEUTICSNEW+65.7K65.7K+$3M$3M
OLMAOLEMA PHARMACEUTICALNEW+883.1K883.1K+$2M$2M
SYKSTRYKER CORPNEW+10.4K10.4K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2022

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1UNHUNITEDHEALTH GRP INChistory →COM3.30%$17M33.1K
2HQYHEALTHEQUITY INChistory →COM3.08%$16M233.1K
3BMRNBIOMARIN PHARMAC INChistory →COM2.73%$14M163.2K
4EVHEVOLENT HEALTH INChistory →CL A2.63%$13M372.1K
5INARI MED INCCOM2.61%$13M182.3K
6IRTCIRHYTHM TECHNOLOGIEShistory →COM2.54%$13M102.9K
7R1 RCM INCCOM2.49%$13M682.6K
8PTCTPTC THERAPEUTICS Ihistory →COM2.36%$12M238.9K
9ARVNARVINAS INChistory →COM2.19%$11M249.6K
10JNJJOHNSON & JOHNSONhistory →COM2.18%$11M67.8K
11IM8NINSMED INChistory →COM2.18%$11M514.1K
12ICON PLCSHS1.95%$10M53.9K
13PRVAPRIVIA HEALTH GROUPhistory →COM1.83%$9M273.2K
14ATRCATRICURE INChistory →COM1.74%$9M226.5K
15EX9EXELIXIS INChistory →COM1.71%$9M553.4K
168INSYNEOS HEALTH INChistory →CL A1.70%$9M182.9K
17APLSUSDAPELLIS PHARMACEUTIChistory →COM1.67%$8M124.0K
18SWAVUSDSHOCKWAVE MEDICALhistory →COM1.62%$8M29.6K
19LNTHLANTHEUS HLDGS INChistory →COM1.60%$8M115.7K
20AXNX*AXONICS INChistory →COM1.59%$8M114.3K
21AGILITI INCCOM1.57%$8M557.7K
22DNLIDENALI THERAPEUTICShistory →COM1.47%$7M243.3K
23INSPINSPIRE MED SYS INChistory →COM1.46%$7M41.8K
242655787DBLUEPRINT MEDICINEShistory →COM1.43%$7M109.9K
25ABBVABBVIE INChistory →COM1.40%$7M53.0K
26BLUBELLUS HEALTH INChistory →COM NEW1.28%$6M614.4K
27CINCOR PHARMA INCCOM1.26%$6M195.5K
28TVTXTRAVERE THERAPEUTICShistory →COM1.21%$6M249.7K
29PROMETHEUS BIOSCIENCCOM1.20%$6M103.2K
30AM6AMICUS THERAPEUTICShistory →COM1.18%$6M572.7K
31LLYLILLY ELI & COhistory →COM1.17%$6M18.4K
32RCUSARCUS BIOSCIENCEShistory →COM1.17%$6M227.0K
33HORIZON THERAPEUTICSSHS1.15%$6M94.5K
34AMLXAMYLYX PHARMACEUTIChistory →COM1.14%$6M205.4K
35ITCIEURINTRA CELLULAR THERAhistory →COM1.12%$6M122.5K
36PFEPFIZER INChistory →COM1.12%$6M129.4K
37CTIC1USDCTI BIOPHARMA CORPhistory →COM1.11%$6M968.3K
38SPRYSILVERBACK THERAPEUThistory →COM1.09%$6M1.05M
39HALOHALOZYME THERAPEUTIChistory →COM1.07%$5M137.4K
40HUMHUMANA INChistory →COM1.06%$5M11.1K
41TMCITREACE MED CONCEPThistory →COM1.06%$5M243.7K
42THCTENET HEALTHCAREhistory →COM1.03%$5M101.5K
43ALKERMES PLCSHS1.02%$5M232.4K
44SILKUSDSILK ROAD MEDICALhistory →COM1.01%$5M114.0K
45ABTABBOTT LABSCOM0.99%$5M51.7K
46MRKMERCK & CO INCCOM0.98%$5M57.8K
47BSXBOSTON SCIENTIFICCOM0.97%$5M127.0K
48BMYBRISTOL MYERS SQUIBBCOM0.92%$5M65.5K
49ALNYALNYLAM PHARMACUETCLCOM0.89%$5M22.7K
50STAASTAAR SURGICAL COCOM0.87%$4M62.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$121M77May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$125M74Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$162M82Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$151M94Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$128M84May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$150M86Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$169M90Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$246M97Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$254M92May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$232M104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$514M123Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$600M121Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$520M118May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$517M120Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$508M109Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$496M112Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$563M106May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$664M108Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B127Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.3B113May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.4B97Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.2B88Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B191Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$521M65May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$670M65Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$580M63Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$836M92Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$831M106May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$736M104Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.